BioNxt advances sublingual everolimus ODF; large-animal PK study begins
BioNxt is advancing its sublingual everolimus ODF for organ transplant rejection and has initiated a large-animal pharmacokinetic study.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.